Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines. Post navigation Officials Cast Doubt on a Dementia Drug, but Human Trials ContinueIn Japan’s Countryside, Century-Old Firms Learn to Embrace Foreign Workers
